LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
05 6월 2008 - 7:00PM
Business Wire
Laboratory Corporation of America� Holdings (LabCorp�) (NYSE:LH),
one of the world�s leading clinical trials and genetic testing
laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a
biopharmaceutical company focused on the development and
commercialization of clinical-stage product candidates for central
nervous system disorders, today announced an exclusive alliance to
develop and commercialize a series of diagnostic tests for genetic
markers identified by Vanda in the course of its clinical
development of Fanapta� (iloperidone), a novel atypical
antipsychotic drug candidate under FDA review for the treatment of
schizophrenia. Financial terms of the agreement were not disclosed.
Vanda has identified a series of pharmacogenetic markers during its
development of Fanapta�, and the company continues its pioneering
work in this area. Under the terms of the collaboration, LabCorp
will be Vanda�s exclusive commercialization partner for tests for
genetic markers of the Fanapta� program. �Working with innovative
companies like Vanda to commercialize predictive medicine tests is
a critical strategic focus for LabCorp,� said Andrew J. Conrad,
Ph.D., Chief Scientist and Global Head of Clinical Trials for
LabCorp. �This collaboration is an example of our commitment to the
advancement of personalized medicine and represents a successful
translation of a research based assay into a valuable diagnostic
test. This relationship is consistent with our focus on companion
diagnostics.� �We are pleased to be collaborating with LabCorp in
this important effort,� said Mihael H. Polymeropoulos, M.D., CEO of
Vanda Pharmaceuticals Inc. �LabCorp�s diagnostic development
expertise, world-class testing capabilities, and national
distribution network make them an ideal choice.� Schizophrenia is a
chronic, severe, and disabling mental disorder that affects more
than two million Americans and approximately one percent of the
world�s adult population. Patients suffering from schizophrenia
exhibit a range of symptoms, including: positive symptoms, such as
hallucinations and delusions; negative symptoms, such as emotional
withdrawal; and cognitive symptoms associated with significant
impairment in social and occupational functioning. About LabCorp�
Laboratory Corporation of America� Holdings, a S&P 500 company,
is a pioneer in commercializing new diagnostic technologies and the
first in its industry to embrace genomic testing. With annual
revenues of $4.1 billion in 2007, over 26,000 employees nationwide,
and more than 220,000 clients, LabCorp offers clinical assays
ranging from routine blood analyses to HIV and genomic testing.
LabCorp combines its expertise in innovative clinical testing
technology with its Centers of Excellence: The Center for Molecular
Biology and Pathology, National Genetics Institute, Inc., ViroMed
Laboratories, Inc., The Center for Esoteric Testing, DIANON
Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation,
Endocrine Sciences, and Cytometry Associates laboratories. LabCorp
conducts clinical trial testing through its Esoterix Clinical
Trials Services division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about
our organization, visit our Web site at: www.labcorp.com. Each of
the above forward-looking statements is subject to change based on
various important factors, including without limitation,
competitive actions in the marketplace and adverse actions of
governmental and other third-party payors. Actual results could
differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could
affect LabCorp�s financial results is included in the Company�s
Form 10-K for the year ended December 31, 2007, and subsequent SEC
filings. About Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals
Inc. (Nasdaq: VNDA) is a biopharmaceutical company focused on the
development and commercialization of clinical-stage product
candidates for central nervous system disorders. To learn more
about Vanda, please visit www.vandapharma.com. Cautionary Note
Regarding Forward-Looking Statements Various statements in this
release are �forward-looking statements� under the securities laws.
Words such as, but not limited to, �believe,� �expect,�
�anticipate,� �estimate,� �intend,� �plan,� �targets,� �likely,�
�will,� �would,� and �could,� and similar expressions or words,
identify forward-looking statements. Forward-looking statements are
based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Vanda is at an early
stage of development and may not ever have any products that
generate significant revenue. Important factors that could cause
actual results to differ materially from those reflected in the
company�s forward-looking statements include, among others: delays
in the completion of Vanda�s clinical trials; a failure of Vanda�s
product candidates to be demonstrably safe and effective; Vanda�s
failure to obtain regulatory approval for its products or to comply
with ongoing regulatory requirements; a lack of acceptance of
Vanda�s product candidates in the marketplace, or a failure to
become or remain profitable; Vanda�s inability to obtain the
capital necessary to fund its research and development activities;
Vanda�s failure to identify or obtain rights to new product
candidates; Vanda�s failure to develop or obtain sales, marketing
and distribution resources and expertise or to otherwise manage its
growth; a loss of any of Vanda�s key scientists or management
personnel; losses incurred from product liability claims made
against Vanda; a loss of rights to develop and commercialize
Vanda�s products under its license and sublicense agreements and
other factors that are described in the �Risk Factors� section
(Part II, Item�1A) of Vanda�s quarterly report on Form 10-Q for the
quarter ended March 31, 2008 (File No. 000-51863). In addition to
the risks described above and in Part II, Item 1A of Vanda�s
quarterly report on Form 10-Q, other unknown or unpredictable
factors also could affect Vanda�s results. There can be no
assurance that the actual results or developments anticipated by
Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved. All
written and verbal forward-looking statements attributable to Vanda
or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements contained or referred to
herein. Vanda cautions investors not to rely too heavily on the
forward-looking statements Vanda makes or that are made on its
behalf. The information in this release is provided only as of the
date of this release, and Vanda undertakes no obligation, and
specifically declines any obligation, to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024